Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: a review of trial reports (Q33330501)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: a review of trial reports	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1 reference

Europe PubMed Central

Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: a review of trial reports (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

revascularization

1 reference

based on heuristic

inferred from title

acute coronary syndrome

1 reference

based on heuristic

inferred from title

2

object named as

Califf RM

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

author name string

Kong DF

1

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

publication date

1 October 1999

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

609-620

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Compl

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential economic impact of glycoprotein IIb-IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mortality by cause for eight regions of the world: Global Burden of Disease Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Can improved quality of care reduce the costs of managing angina pectoris?

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term administration of glycoprotein IIb/IIIa antagonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events i

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tiro

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Persistent activation of coagulation mechanism in unstable angina and myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Design of a new class of orally active fibrinogen receptor antagonists.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

https://pubmed.ncbi.nlm.nih.gov/10551433

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-199958040-00003

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33330501&oldid=2195250107"